Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: say good-bye to some share pricing highs!

November 27, 2018 8:17am

Good news, bad press or the lack of makes markets melt just as Icarus had wings of feathers and wax

Out and about: Are the CRISPRS: CRSP (close +$0.82), EDIT (close +$0.73) and NTLA (-$0.02) about to feel more downside pressures over news of a Chinese scientist who used a powerful gene-editing technique to change the embryonic DNA of twins drew fire from ethicists and doctors in Massachusetts and from a professor at MIT who helped invent the tool.

Pre-open indications: 5 SELLs

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!

A trusted source of factual reporting of preludes and aftermaths!

There’s a difference between trust and conviction. Trust is something you can rely on, beyond certainty. Conviction doesn't demand that you, or anyone else, play by the rules. After gains, there’s pain; followed by advances, declines and other progressions or was it regressions?

U.S. stock index futures are headed south …

Dow futures are DOWN -0.39% (-96 points) and NASDAQ futures are DOWN -0.61% (-41 points)

U.S. stock index futures fell ahead of Tuesday's open amid renewed concerns over U.S.-China trade relations;

European markets trade lower amid fresh trade concerns;

Asian markets traded higher as investors wait for Trump and Xi's meeting;

Data docket: the latest S&P Corelogic Case-Shiller home price index is slated to come out at 9 a.m. ET, followed by consumer confidence figures at 10 a.m. ET.

Tuesday’s indications:

The iShares Nasdaq Biotechnology (IBB) is NOT indicating
The SPDR S&P Biotech ETF (XBI) is NOT indicating
The Health Care Select Sector SPDR ETF (XLV) is NOT indicating
The iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.49% DOWNSIDE

Henry’omics:

The moves in U.S. futures come after Monday’s session finished sharply higher, with the Dow closing more than 350 points higher. Looking overseas, markets appear somewhat cautious with Asia closing mostly in the black; with Europe trading slightly lower <CNBC>.

I am RESUMING my cautious approach to ANY new purchases; I perceive a run on the upside!

Last night’s closing bell remarks, “sector stays up on what as the NASDAQ (+2%) and IBB (+1.7%) jump?

Monday night’s percentage (%) indicators:

Review the range of the 25 upside from +0.48% (BLCM) to +8.09% (FATE) while the 18 downside ranged from -0.12% (NTLA) to -8.13% (AST -$0.10) with a 2 flat close (BSTG and CLBS).

Volume stat:

5 out of the 25 upside had higher (than the 3 month average) volume
7 out of 18 downside experienced greater volume (than the 3 month average).

In 18 sessions in November – there were 1 holiday, 8 positive closes, 1 neutral and 8 negative closes

In 23 sessions in October – there were 17 negative closes and 6 positive sessions;
In 19 sessions in September – there were 10 negative closes and 9 positive sessions;
In 21 August sessions – 6 had negative and 15 had positive closes

Companies in my headlights – It’s your decision; I provide an idea and context:

bluebird bio (BLUE) closed up +$6.10 to $128.24 and has a negative -$1.28 or -1% aftermarket indication – SELL;

Alnylam Pharmaceuticals (ALNY) closed up +$5.01 to $78.35 and has a negative -$0.78 or -0.99% aftermarket indication – SELL;

Are CRISPR Therapeutics (CRSP close +$0.82), Editas Medicine (EDIT close +$0.73) and Intellia Therapeutics (NTLA (-$0.02) going to be hit HARD by the news cycle when a Chinese scientist who used a powerful gene-editing technique to change the embryonic DNA of twins drew fire from ethicists and doctors in Massachusetts and from a professor at MIT who helped invent the tool - SELL

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.